Scaldis Pharma SRL
0.7 FTEScaldis Pharma reported total assets of 251,161 € at the end of the 2025 financial year (annual accounts filed with the NBB on 30 Jun 2026), with 0.7 full-time equivalent.
The score of Scaldis Pharma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2023 → 2025: Equity -47 % Total assets +609 %
Accounts of the company itself (not consolidated).
The full file covers 3 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Scaldis Pharma's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 30 Jun 2026
- Year ended 31 Dec 2024filed on 06 Jun 2025
- Year ended 31 Dec 2023filed on 29 Jun 2024
Scaldis Pharma's financial analysis
- Solvency2.3%sector median: 47.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Scaldis Pharma
Scaldis Pharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0803.923.429
- VAT number
- BE0803923429
- Peppol
- Registered · 0208:0803923429 · as of 13 Nov 2026
- Legal form
- SRL
- Incorporated
- 13 Jul 2023
- Registered office
- 9310 Aalst
- Size
- Micro · 0.7 FTE
- Latest accounts
- 2025 · filed on 30 Jun 2026
- Activity
- Manufacture of medicaments (NACE 21201)
Scaldis Pharma (SRL) has been based in Aalst since 2023, active in: manufacture of medicaments. For 2025, it reports a net loss of 14,039 € and equity of 5,697 €; its revenue is not published. With 0.7 full-time equivalents, it is a micro-enterprise by headcount.
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Scaldis Pharma
Companies in the same business, of comparable size and area, outside its group.
- Groovy.Bio Manufacture of pharmaceutical preparations Evergem · balance sheet 744,069 €
- Alnylam Belgium Wholesale of pharmaceutical and medical goods Brussels · balance sheet €1.20m
- ExoXpert Manufacture of pharmaceutical preparations Liège · balance sheet €2.05m
- -Heel Belgium Manufacture of pharmaceutical preparations Ghent · balance sheet €3.17m
- White Raven Manufacture of pharmaceutical preparations Liège · balance sheet €9.55m
- Phoenix Biosciences Manufacture of pharmaceutical preparations Nivelles · balance sheet €8.11m
- Etherna Immunotherapies Research and experimental development on natural sciences and engineering Niel · balance sheet €12.8m
- Hyloris Developments Manufacture of pharmaceutical preparations Liège · balance sheet €20.6m
Frequently asked questions about Scaldis Pharma
What is the revenue of Scaldis Pharma?
Scaldis Pharma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Scaldis Pharma?
In Belgium, the VAT number is the company number prefixed with BE: BE0803923429 for Scaldis Pharma, if the company is VAT-registered. Its company number (CBE) is 0803.923.429.
Where is the registered office of Scaldis Pharma?
According to the CBE register, the registered office of Scaldis Pharma is in 9310 Aalst.
What is the equity of Scaldis Pharma?
At the close of the 2025 financial year, the equity of Scaldis Pharma amounts to 5,697 €, a solvency of 2.3% of total assets.
How many people work at Scaldis Pharma?
0.7 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Scaldis Pharma?
The register lists 1 active mandates at Scaldis Pharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Scaldis Pharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →